Celladon Corporation postpones $75 million IPO

By
A A A

Celladon Corporation, which is developing a first-in-class gene therapy for patients with systolic heart failure, postponed its IPO on Wednesday, citing poor market conditions. The San Diego, CA-based company was founded in 2000 and has yet to generate revenue. Celladon Corporation initially filed confidentially on 9/6/2013. J.P. Morgan and Barclays were set to be the joint bookrunners on the deal.



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: CLDN

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

100%

Most Active by Volume

44,823,339
  • $75.19 ▲ 0.28%
43,744,171
  • $3.44 ▼ 0.29%
42,340,022
  • $97.671 ▲ 0.66%
34,178,145
  • $17.62 ▼ 1.23%
34,028,998
  • $15.59 ▼ 0.19%
32,055,708
  • $21.23 ▼ 2.41%
31,539,235
  • $3.76 ▲ 0.80%
30,434,619
    $34.25 unch
As of 7/25/2014, 04:03 PM